期刊
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY
卷 12, 期 -, 页码 119-136出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/BLCTT.S327016
关键词
multiple myeloma; CAR T-cell; immunotherapy
类别
CAR T-cell therapies show potential in the treatment of multiple myeloma, but still face challenges.
The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric antigen receptor (CAR) T-cell therapies have improved outcomes of patients with hematologic malignancies. B-cell maturation antigen (BCMA) is the current target antigen of choice for most CAR T-cell products under investigation for MM. However, their shortcomings deal with logistical and clinical challenges, including limited availability, manufacturing times, and toxicities. This article provides an overview of recently developed and investigational CAR T-cell therapies for MM, highlighting current evidence and challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据